Medical Economics April 10, 2025
Key Takeaways
- The Trump administration’s transparency initiative seeks to empower patients with clear healthcare pricing information, but compliance from hospitals and insurers remains uncertain.
- Hospitals and PBMs are criticized for their lack of transparency, contributing to inflated drug costs and hindering patient access to savings.
- The 340B program’s misuse by hospitals and PBMs’ profit-driven practices highlight the need for reform to ensure savings benefit patients.
- Enforcing transparency in healthcare pricing could reduce costs and improve quality, aligning with broader healthcare reform objectives.
Without clear pricing, patients can end up paying thousands more than necessary.
“Radical transparency” has become a favorite phrase of the Trump administration. The president recently signed an executive order that aims to “empower patients with...







